Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Return on Capital Employed (2021 - 2025)

Lyell Immunopharma (LYEL) has disclosed Return on Capital Employed for 5 consecutive years, with 0.83% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 11.0% to 0.83% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.83% through Dec 2025, down 11.0% year-over-year, with the annual reading at 0.74% for FY2025, 10.0% down from the prior year.
  • Return on Capital Employed hit 0.83% in Q4 2025 for Lyell Immunopharma, up from 0.94% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.18% in Q3 2021 to a low of 0.96% in Q2 2025.
  • Historically, Return on Capital Employed has averaged 0.42% across 5 years, with a median of 0.3% in 2023.
  • Biggest five-year swings in Return on Capital Employed: rose 1bps in 2023 and later tumbled -61bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.19% in 2021, then dropped by -6bps to 0.2% in 2022, then plummeted by -65bps to 0.33% in 2023, then tumbled by -114bps to 0.72% in 2024, then decreased by -16bps to 0.83% in 2025.
  • Business Quant data shows Return on Capital Employed for LYEL at 0.83% in Q4 2025, 0.94% in Q3 2025, and 0.96% in Q2 2025.